This article is more than 5 years old. Information may no longer be current.

NxStage’s new System One gets FDA approval

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NxStage Medical Inc.’s next generation System One hemodialysis system has received clearance from the U.S. Food and Drug Administration. The system consists of new features and capabilities, including a new touchscreen user interface and integrated blood pressure monitor designed to enhance ease of use for patients performing home hemodialysis.

The device was approved in Europe in March.

"Early customer and patient feedback in the UK on our next generation system has been very positive, validating many of the benefits we expected," said NxStage President Joseph E. Turk. "We are very excited to bring these new features and capabilities that are designed to significantly improve our patients' therapy experience to the US market. The touch screen interface provides an excellent platform to continue bringing new features and functionality moving forward."